文献速递糖尿病

糖尿病预防计划不同治疗分组、糖尿病状态、糖尿病病程及累积血糖暴露下的远端对称性多神经病变患病率

Prevalence of Distal Symmetrical Polyneuropathy by Diabetes Prevention Program Treatment Group, Diabetes Status, Duration of Diabetes, and Cumulative Glycemic Exposure.
PubMed 文献 · Diabetes Care · 2024-01-01

在糖尿病预防计划(DPP)随机化约21年后,评估远端对称性多神经病变(DSPN)与治疗分组、糖尿病状态/病程及累积血糖暴露的关联。DSPN患病率在各初始治疗组间无差异(强化生活方式21.5%、二甲双胍21.5%、安慰剂21.9%),但与糖尿病、更长糖尿病病程及更高时间加权HbA1c相关。

要点

  • DPP随机化21年后,66%受试者患糖尿病,DSPN患病率在初始治疗分组间无差异。
  • DSPN患病率在有糖尿病风险者19.6% vs 糖尿病患者22.7%,与更长糖尿病病程及时间加权HbA1c相关(P<0.001)。
  • 强化生活方式与年龄存在显著交互作用(P<0.05),对老年人DSPN可能有长期获益。

核心结论

  • DSPN的可能性在DPP各治疗组间相似,但在糖尿病患者、更长糖尿病病程及更高累积血糖暴露者中更高。
  • 强化生活方式可能对老年人DSPN有长期获益。

研究设计与样本

  • DPP将3234名≥25岁糖尿病高风险成人随机分配至强化生活方式、二甲双胍或安慰剂干预以预防糖尿病。
  • DPP结束后2779人加入糖尿病预防计划结局研究(DPPOS),继续开放标签二甲双胍、停止安慰剂、提供半年一次小组课程形式的强化生活方式及季度生活方式课程。
  • 在DPPOS第17年对1792名参与者评估DSPN症状和体征,采用多变量逻辑回归模型评估关联。

主要发现

  • DPP随机化21年后,66%受试者患糖尿病。
  • DSPN患病率不因初始DPP治疗分配而异:强化生活方式21.5%、二甲双胍21.5%、安慰剂21.9%。
  • 强化生活方式治疗分配与年龄对DSPN存在显著交互作用(P<0.05)。
  • 在DPPOS第17年,与强化生活方式相比,安慰剂组DSPN的比值比随5岁年龄间隔增加而降低17.4%(95%CI 3.0, 29.3)。
  • DSPN患病率在有糖尿病风险者中为19.6%,低于糖尿病患者的22.7%,并与更长糖尿病病程及时间加权HbA1c相关(P值<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess associations between distal symmetric polyneuropathy (DSPN) and Diabetes Prevention Program (DPP) treatment groups, diabetes status or duration, and cumulative glycemic exposure approximately 21 years after DPP randomization. RESEARCH DESIGN AND METHODS: In the DPP, 3,234 adults ≥25 years old at high risk for diabetes were randomized to an intensive lifestyle (ILS), metformin, or placebo intervention to prevent diabetes. After the DPP ended, 2,779 joined the Diabetes Prevention Program Outcomes Study (DPPOS). Open-label metformin was continued, placebo was discontinued, ILS was provided in the form of semiannual group-based classes, and all participants were offered quarterly lifestyle classes. Symptoms and signs of DSPN were assessed in 1,792 participants at DPPOS year 17. Multivariable logistic regression models were used to evaluate DSPN associations with treatment group, diabetes status/duration, and cumulative glycemic exposure. RESULTS: At 21 years after DPP randomization, 66% of subjects had diabetes. DSPN prevalence did not differ by initial DPP treatment assignment (ILS 21.5%, metformin 21.5%, and placebo 21.9%). There was a significant interaction between treatment assignment to ILS and age (P < 0.05) on DSPN. At DPPOS year 17, the odds ratio for DSPN in comparison with ILS with placebo was 17.4% (95% CI 3.0, 29.3) lower with increasing 5-year age intervals. DSPN prevalence was slightly lower for those at risk for diabetes (19.6%) versus those with diabetes (22.7%) and was associated with longer diabetes duration and time-weighted HbA1c (P values <0.001). CONCLUSIONS: The likelihood of DSPN was similar across DPP treatment groups but higher for those with diabetes, longer diabetes duration, and higher cumulative glycemic exposure. ILS may have long-term benefits on DSPN for older adults.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lee CG, Ciarleglio A, Edelstein SL, et al. Prevalence of Distal Symmetrical Polyneuropathy by Diabetes Prevention Program Treatment Group, Diabetes Status, Duration of Diabetes, and Cumulative Glycemic Exposure. Diabetes Care. 2024. PMID: 38502874. doi:10.2337/dc23-2009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。